Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Vivoryon Therapeutics NV's EV-to-OCF or its related term are showing as below:
WBO:VVYN'
s EV-to-OCF Range Over the Past 10 Years
Min: -32.65 Med: -1.41 Max: 0.79
Current: -4.36
During the past 13 years, the highest EV-to-OCF of Vivoryon Therapeutics NV was 0.79. The lowest was -32.65. And the median was -1.41.
WBO:VVYN's EV-to-OCF is ranked better than 53.55% of 1408
companies
in the Biotechnology industry
Industry Median: -3.68
vs WBO:VVYN: -4.36
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivoryon Therapeutics NV's PE Ratio (TTM) for today is calculated as:
Vivoryon Therapeutics NV's share price for today is €1.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vivoryon Therapeutics NV EV-to-OCF Related Terms
Vivoryon Therapeutics NV EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VVYN vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, Vivoryon Therapeutics NV's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivoryon Therapeutics NV EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vivoryon Therapeutics NV's EV-to-OCF falls into.
Vivoryon Therapeutics NV's current Enterprise Value is €31.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-7.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivoryon Therapeutics NV (WBO:VVYN) has a EV-to-OCF of -4.36 as of Sep. 04, 2026. According to the industry distribution chart, Vivoryon Therapeutics NV ranks #654 out of 1408 companies in the Biotechnology industry, placing it in the top 46.4%.
Is Vivoryon Therapeutics NV's EV-to-OCF too high?
Vivoryon Therapeutics NV's current EV-to-OCF is -4.36. Based on the distribution chart, Vivoryon Therapeutics NV ranks #654 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vivoryon Therapeutics NV has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivoryon Therapeutics NV ranks #654 out of 1408 companies for EV-to-OCF. This puts Vivoryon Therapeutics NV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Vivoryon Therapeutics NV's current EV-to-OCF is -4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (WBO:VVYN) has a current EV-to-OCF of -4.36. The current EV-to-OCF is -4.36. Vivoryon Therapeutics NV's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vivoryon Therapeutics NV (WBO:VVYN), the current EV-to-OCF is -4.36 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
15GF Score
Get the complete analysis for WBO:VVYN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VVYN has been successfully added to your 
